Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Radotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 12/20 | 0.99 |
| ▸ | BCR known ✓ | P11274 | 4/20 | 0.99 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.99 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.99 |
| ▸ | KDR | P35968 | 1/20 | 0.99 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.99 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.99 |
| ▸ | KIT | P10721 | 11/20 | 0.82 |
| ▸ | LDLR | P01130 | 8/20 | 0.82 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.82 |
| ▸ | LCK | P06239 | 4/20 | 0.82 |
| ▸ | LYN | P07948 | 4/20 | 0.82 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.82 |
| ▸ | FLT3 | P36888 | 4/20 | 0.82 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.82 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.82 |
| ▸ | SRC | P12931 | 2/20 | 0.82 |
| ▸ | RAF1 | P04049 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radotinib SCHEMBL15285797 | 1.00 | ABL1 (0.99) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL15318848 | 0.99 | ABL1 (0.97) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL29366343 | 0.99 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL29381661 | 0.99 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL3359952 | 0.99 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| SCHEMBL3945090 | 0.91 | ABL1 (0.85) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL434496 | 0.91 | ABL1 (0.99) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL28656586 | 0.91 | ABL1 (0.99) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL1459790 | 0.91 | ABL1 (0.99) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL31005052 | 0.91 | ABL1 (0.99) | ABL1BCRADORA3NR1I2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102147-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-18 | — | — | US | disclosed |
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| WO-2025101588-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025101571-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-X L DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025101575-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-X L DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240043531-A1 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2024-02-08 | — | — | US | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | TREELINE BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2023215471-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215449-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-4190816-A1 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | Akeso Biopharma, Inc. (CN) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022218384-A1 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | 中山康方生物医药有限公司 | 2022-10-20 | — | — | WO | disclosed |
| CN-115192718-A | anti-CD47 monoclonal antibody and application thereof | 中山康方生物医药有限公司 | 2022-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2, BCL2L10, BCL2L1 | ABL1 136/4885BCR 29/4885ADORA3 4612/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | ABL1 595/4885BCR 31/4885ADORA3 2990/4885 |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | ABL1 285/4885BCR 17/4885ADORA3 2807/4885 |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | ABL1 1237/4885BCR 121/4885ADORA3 3500/4885 |
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2L1, BCL2, BCL2L10 | ABL1 310/4885BCR 29/4885ADORA3 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.